

March 28, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited will be discontinuing with the manufacturing and marketing of the product Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) from April 1, 2025.

Imdur is currently being indicated for Prophylactic treatment of angina pectoris.

We request you to take the above intimation on record.

Thanking you

Yours faithfully

For **AstraZeneca Pharma India Limited**

Manasa. R

Company Secretary